OPS encapsulation for enhanced herbicide efficacy and sustainability
OPS technology enhances Pendimethalin and Atrazine herbicides through encapsulation, improving weed control, reducing leaching, and extending residual activity. This innovation offers a sustainable solution for agriculture by minimizing environmental impact and meeting regulatory standards.
Overview
OPS (Olive Pomace-derived Nanoparticles) technology offers a groundbreaking approach to herbicide application by encapsulating active ingredients of Pendimethalin and Atrazine. This encapsulation ensures a controlled release, which not only improves efficacy but also minimizes environmental impact. By reducing leaching and extending the residual activity of these herbicides, OPS technology provides more consistent weed control and decreases the frequency of applications. This results in a more sustainable agricultural practice that aligns with both market demands and regulatory standards.
Technical specifications
- Encapsulation technology: Utilizes nanoencapsulation of active ingredients for controlled release.
- Herbicides: Focused on Pendimethalin and Atrazine.
- Benefits:
- 25% increase in efficacy over non-encapsulated formulations.
- 35% reduction in leaching, enhancing environmental safety.
- Prolonged residual activity for extended weed control.
- Field trials: Conducted across varied climates to measure efficacy, leaching, and residual activity.
Technology readiness level
Currently at TRL 5, OPS technology has moved from concept validation in a laboratory setting to testing in relevant environments through field trials. This stage involves comprehensive field evaluations to ensure regulatory compliance and readiness for commercial application.
About Veos Pharmaceuticals
Veos Pharmaceuticals is a Madrid-based biotechnology company that develops and commercializes science-backed solutions across human health, agriculture, and environmental sustainability. Founded in 2023, the company operates as a vertically integrated entity, maintaining direct control over research, formulation, regulatory compliance, and distribution across Europe and North America. Its platform-based innovation model is built on scientific rigor and commercial discipline, resulting in a portfolio of more than 40 commercial products. By combining internal R&D with selective in-licensing and strategic partnerships, Veos translates validated research into scalable, real-world applications. The firm distinguishes itself through its focus on profitability, which it has maintained since 2024, and its commitment to manufacturing standards, leveraging European facilities to ensure quality and regulatory adherence.
The company's work provides critical value to diverse stakeholders, including patients, clinicians, growers, and industrial partners. Its human health platform delivers pharmaceutical and nutraceutical products targeting areas such as ophthalmology and muscle health, while its agricultural and environmental platforms focus on enhancing crop resilience, water treatment, and material recovery. Through its direct-to-consumer and business-to-business channels, Veos addresses specific market needs with evidence-based technologies. The company’s growth is supported by a senior leadership team with extensive expertise in pharmaceutical operations and biotechnology, and it actively collaborates with research institutions and global distributors to expand the deployment and impact of its technologies.
Inquire about this partnering listing
Industry applications
delivered to your inbox.